Pivmecillinam is a prodrug of the beta lactam antibiotic mecillinam, indicated for the treatment of uncomplicated urinary tract infections (UTIs). Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa.
- Mechanism
- Curator reviewed
Pivmecillinam interferes with the biosynthesis of the bacterial cell wall however its activity is slightly different from that of other penicillins and cephalosporins
- Primary indication
- Pivmecillinam is indicated for the treatment of uncomplicated urinary tract infections caused by sensitive strains of E. coli, Klebsiella species, Enterobacteria species, Staphylococcus, and Proteus species.Curator reviewed · 7 structured indications
- Formula / weight
- C21H33N3O5S · 439.569 g/mol (avg)
- First approval
- Canada, 2024 · United States, 2026
- Also known as
- Amdinocillin pivoxil
- Code names
- RO 10-9071
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
NPGNOVNWUSPMDP-HLLBOEOZSA-NSMILES[H]C(=N[C@@H]1C(=O)N2[C@@H](C(=O)OCOC(=O)C(C)(C)C)C(C)(C)S[C@]12[H])N1CCCCCC1Targets
What you can answer from here — as of September 13, 2026
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Pivmecillinam, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account